358 results on '"Champiat, S."'
Search Results
2. 6O Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials
3. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
4. Novel patterns of response under immunotherapy
5. 137P First-in-human results from a phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
6. Safety and efficacy of antibody drug conjugates in older patients with solid tumors
7. ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART
8. Les cardiomyopathies toxiques liées aux chimiothérapies
9. Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection
10. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
11. Immune-related adverse events with immune checkpoint blockade: a comprehensive review
12. 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
13. 85P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
14. 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
15. 2P Outcomes of patients with gynecological tumors harboring HER2 defects: A single center study based on Gustave Roussy cancer center’s molecular program
16. Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)
17. 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer
18. Use of the Geriatric Core Dataset for older patients included in early phase trials
19. Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors
20. Better than RECIST and faster than iRECIST: Defining the immunotherapy progression decision score to better manage progressive tumors on immunotherapy
21. 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study
22. OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
23. 508P High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors
24. 732MO The combination of ICT01, a γ9δ2 T cell-activating mAb, plus pembrolizumab induces a broad antitumor immune response and disease control in patients with CPI-failure melanoma, NSCLC and bladder cancer: EVICTION trial
25. 1026P Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
26. 1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
27. 661P Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
28. 657P Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
29. 607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors
30. 469P Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
31. P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
32. Checkpoint immunologique comme cible thérapeutique
33. Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?
34. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
35. Réponses abscopales chez les patients atteints de mélanome métastatique : étude de cohorte multicentrique nationale
36. Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
37. 1452P Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center
38. 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor
39. 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
40. Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
41. Impact thérapeutique du profilage moléculaire des patients atteints de mélanome résistant au traitement standard : résultats « en vie réelle »
42. SIOG2023-1-P-206 - Safety and efficacy of antibody drug conjugates in older patients with solid tumors
43. 1845P Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?
44. 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
45. 1161P Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
46. 516P Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
47. 2171P Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
48. 2158P A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
49. 822O Activation of γ9δ2 T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial)
50. 263P Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.